

EXHIBIT D1d

August 2024 EBD Medical Drug Recommendations

Drug	Treating Diagnosis	EBRx Recommendation	HA	Cost	EBD Commission	Board of Finance Decision
Actemra	Covid-19, Cytokine release syndrome, Giant cell arteritis, Kidney transplant, Neuromyelitis optica, Rheumatoid arthritis, Systemic sclerosis-associated interstitial lung disease	Exclude		\$37,287 per year - \$49,717 per year based on diagnosis	Approve Recommendation	Approve Recommendation
Adzyna	Congenital thrombotic thrombocytopenic purpura	Cover w/ PA		Prophylaxis dose = \$307,320 per year	Approve Recommendation	Approve Recommendation
Anktiva	Non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)	Exclude		\$644,400	Approve Recommendation	Approve Recommendation
Aphexda	Multiple myeloma	Exclude		\$14,160 (1 dose) / \$28,320 (2 doses)	Approve Recommendation	Approve Recommendation
Beqvez	Gene therapy for Hemophilia B (Factor IX deficiency)	Exclude		\$4.2 million	Approve Recommendation	Approve Recommendation
Elrexio	Relapsed or refractory multiple myeloma	Cover w/ PA		\$566,232 per year	Approve Recommendation	Approve Recommendation
Focinvez	Acute and delayed nausea and vomiting with chemotherapy	Exclude		\$549 per vial	Approve Recommendation	Approve Recommendation
Imdelltra	Accelerated FDA approval for extensive stage small cell lung cancer	Cover w/ PA		\$469,800 per year	Approve Recommendation	Approve Recommendation
Izervay	Intravitreal injection for geographic atrophy secondary to age-related macular degeneration	Exclude		\$60,480 for both eyes per year	Approve Recommendation	Approve Recommendation
Jemperli	Endometrial cancer, solid tumors	Cover w/ PA		\$15,764 per month	Approve Recommendation	Approve Recommendation
Loqtorzi	Nasopharyngeal carcinoma	Cover w/ PA		\$14,266 - \$21,340 per 28 day	Approve Recommendation	Approve Recommendation
Mresvia	RSV vaccine	No EBRx restrictions	Cover	\$348 for lifetime dose	Approve Recommendation	Approve Recommendation
Pemgarda	EUA for pre-exposure prophylaxis of Covid-19	Exclude		\$6,930 per dose	Approve Recommendation	Approve Recommendation
Penbraya	Mening ACYW + B vaccine	No EBRx restrictions	Cover	2 dose series = \$553.50	Approve Recommendation	Approve Recommendation
Rystiggo	Generalized myasthenia gravis AChR(+) or MuSK(+)	Cover w/ PA		\$43,560 per 6 week cycle.	Approve Recommendation	Approve Recommendation
Rytelo	Myelodysplastic syndromes with transfusion dependent anemia	Cover w/ PA		\$35,582 per 28 days	Approve Recommendation	Approve Recommendation

Drug	Treating Diagnosis	EBRx Recommendation	HA	Cost	EBD Commission Decision	Board of Finance Decision
Talvey	Relapsed or refractory multiple myeloma	Cover w/ PA		\$599,532 per year	Approve Recommendation	Approve Recommendation
Tecvayli	Relapsed or refractory multiple myeloma	Cover w/ PA		\$513,352 per year	Approve Recommendation	Approve Recommendation
Tofidence	Rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis.	Exclude		\$27,495 per year - \$36,660 per year based on diagnosis	Approve Recommendation	Approve Recommendation
Tyenne	Rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis.	Cover IV tocilizumab w/ PA		\$27,495 per year - \$36,660 per year based on diagnosis	Approve Recommendation	Approve Recommendation
Winrevair	Pulmonary Arterial Hypertension	Exclude		\$291,200 per year	Approve Recommendation	Approve Recommendation
Xacduro	Hospital acquired pneumonia + Acinetobacter baumannii-calcoaceticus complex	No EBRx restrictions	Cover under DRG	\$190 per infusion. Varied frequency but < 7 days.	Approve Recommendation	Approve Recommendation
Xiaflex	Peyronie disease	Cover w/PA		Max dose of 4 cycles = \$63,210	Approve Recommendation	Approve Recommendation